Showing 2691-2700 of 5771 results for "".
- Alcon Showcases Breakthrough Innovations and New Clinical Data at AAO 2025https://modernod.com/news/alcon-showcases-breakthrough-innovations-and-new-clinical-data-at-aao-2025/2484167/Alcon will highlight a lineup of new technologies and clinical data at the 2025 American Academy of Ophthalmology (AAO) annual meeting, October 18–20, in Orlando. At booth #2120, ophthalmologists, surgical staff,
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- Lovell and DefEYE Partner to Expand Access to Biovance Ocular Biologics Across Federal Healthcare Systemshttps://modernod.com/news/lovell-government-services-and-defeye-partner-to-expand-access-to-biovance-ocular-biologics-across-federal-healthcare-systems/2484164/Lovell Government Services and DefEYE, the provider of Biovance decellularized basement membranes for ocular use, announced a partnership to serve federal healthcare systems, including the Veterans Health Administration, the Department of Defense Military
- Bloomberg Philanthropies Launches $75 Million Vision Initiative to Expand Global Access to Eye Carehttps://modernod.com/news/bloomberg-philanthropies-launches-75-million-vision-initiative-to-expand-global-access-to-eye-care/2484163/Bloomberg Philanthropies announced a $75 million vision initiative to address untreated vision impairment in low- and middle-income countries, as w
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration
- Zeiss to Showcase Advancements in Ophthalmic Visualization and Digital Workflow at AAO 2025https://modernod.com/news/zeiss-to-showcase-advancements-in-ophthalmic-visualization-and-digital-workflow-at-aao-2025/2484161/Zeiss Medical Technology will present its latest innovations in ophthalmic visualization, diagnostics, and digital workflow solutions at the American Academy of Ophthalmology (AAO) annual meeting, taking place October 18–20, 2025, in Orlando.
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- Generational Differences Drive Contact Lens Choices and Technology Appeal, New Research Findshttps://modernod.com/news/generational-differences-drive-contact-lens-choices-and-technology-appeal-new-research-finds/2484156/The motivations for wearing contact lenses and the appeal of new lens technologies vary significantly by generation, according to new research from the Contact Lens Institute (CLI) to be presented this week at the 2025 American Academy of Optometry annual meet
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- Samsara Vision Launches PERSPECTIVE Trial, Achieves First Implant of SING IMT in Pseudophakic Patienthttps://modernod.com/news/samsara-vision-launches-perspective-trial-achieves-first-implant-of-sing-imt-in-pseudophakic-patient/2484154/Samsara Vision announced the initiation and successful first surgery of the PERSPECTIVE clinical trial. The study will evaluate the safety and efficacy of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in pseudophakic patients.